Enliven Therapeutics (ELVN) AI Stock Analysis

• Market Cap: $1.32B
• Dividend Yield: N/A
• Average Volume (3M): 635.47K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.42
• Revenue Growth: N/A
• EPS Growth: 12.85%
• Country: US
• Employees: 62
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -0.57
• Shares Outstanding: 58,990,246
• 10 Day Avg. Volume: 493,328
• 30 Day Avg. Volume: 635,474
• PEG Ratio: 10.76
• Price to Book (P/B): 3.72
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -17.10
• Enterprise Value/Market Cap: 0.89
• Enterprise Value/Revenue: 1.34K
• Enterprise Value/Gross Profit: -14.88K
• Enterprise Value/Ebitda: -2.86
• 1Y Price Target: $42.14
• Price Target Upside: 88.55% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8

• Rating: 36 Underperform
• Price Target: ―

Enliven Therapeutics' stock is challenged by its early-stage financial profile with no revenue and ongoing losses. Despite strong liquidity, the reliance on external financing and lack of profitability weigh heavily. Technical indicators reinforce a cautious approach, as the stock shows bearish trends. Valuation metrics further reflect the typical risk profile of a biotech company in development.

Positive Factors

Clinical Development

The success of the Phase 1 data suggests Enliven is well-positioned to initiate a Phase 3 trial.

Efficacy and Safety

Enliven's '001 is tracking well ahead of the approved/generic TKIs in 3L/3L+ setting—showing markedly better safety and cumulative MMR of 44% vs 15-26% with other TKIs.

Market Opportunity

The market for late line CML is over $3 billion and Enliven is showing high efficacy with a good safety profile in late line patients.

Negative Factors

Adverse Events

16.1% of patients had dose interruptions, 3.4% had dose reductions, and 4.6% discontinued treatment due to a treatment-emergent adverse event.

Competition

There is pressure from generic TKIs in the late line CML setting, which could affect the market positioning of Enliven's '001.

Enliven Therapeutics Business Overview & Revenue Model

Company Description

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.

How the Company Makes Money

Enliven Therapeutics makes money primarily through the development and commercialization of its proprietary therapeutic products. The company's revenue model includes securing funding through partnerships with larger pharmaceutical companies, licensing agreements, and potential milestone payments as their drug candidates progress through clinical trials. Once a therapeutic product receives regulatory approval, Enliven Therapeutics generates revenue through product sales, either directly or via distribution agreements with strategic partners. Additionally, the company may engage in collaborations for research and development, which can provide upfront payments and ongoing royalties based on sales performance.

Enliven Therapeutics Financial Statement Overview

Summary

Enliven Therapeutics is in the early development stage typical of biotech firms, characterized by a lack of revenue and financial losses. While strong liquidity supports operations, the company remains dependent on external financing. Recent improvements in financial stability are notable, but profitability challenges persist.

Income Statement

Enliven Therapeutics has shown a consistent pattern of negative revenue, gross profit, and net income, indicating significant challenges in generating sales and managing costs. The lack of revenue growth and persistent losses highlight the company's early-stage nature in the biotechnology sector, where long development cycles are common.

Balance Sheet

The balance sheet reflects strong liquidity with substantial cash reserves and no debt, supporting operational needs. However, negative stockholders' equity in previous years and current low total liabilities suggest potential financial instability. The company's equity ratio has improved recently, indicating better capital management.

Cash Flow

Cash flow statements indicate negative operating cash flows and free cash flows, which is typical for a biotechnology firm in the development phase. The company has maintained substantial financing activities, reflecting reliance on external capital to support operations. The operating cash flow to net income ratio is below optimal levels, underscoring challenges in converting income to cash.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-317.00K	-297.00K	-622.00K	-99.00K	-97.00K
EBITDA	-88.47M	-81.93M	-38.58M	-24.65M	-9.27M
Net Income	-89.02M	-71.58M	-37.75M	-24.72M	-18.93M
Balance Sheet
Total Assets	325.76M	271.87M	83.30M	113.33M	131.00M
Cash, Cash Equivalents and Short-Term Investments	313.44M	253.15M	75.54M	110.02M	130.37M
Total Debt	0.00	335.00K	323.00K	159.00K	105.00K
Total Liabilities	15.91M	25.96M	160.12M	156.22M	151.31M
Stockholders Equity	309.85M	245.91M	-76.83M	-42.89M	-20.30M
Cash Flow
Free Cash Flow	-73.24M	-61.42M	-32.69M	-19.32M	-8.99M
Operating Cash Flow	-73.19M	-61.27M	-32.08M	-19.13M	-8.53M
Investing Cash Flow	-36.00M	-148.41M	-612.00K	-191.00K	-461.00K
Financing Cash Flow	133.16M	234.29M	-1.80M	-1.02M	130.51M

Enliven Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 22.35
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ELVN, the sentiment is Positive. The current price of 22.35 is above the 20-day moving average (MA) of 21.45, above the 50-day MA of 20.25, and above the 200-day MA of 22.09, indicating a bullish trend. The MACD of 0.53 indicates Positive momentum. The RSI at 54.82 is Neutral, neither overbought nor oversold. The STOCH value of 32.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ELVN.

Enliven Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VRDN	61 Neutral	$1.46B	―	-49.41%	―	4.86%	10.13%
NTLA	61 Neutral	$1.40B	―	-57.92%	―	-13.37%	2.57%
ABCL	59 Neutral	$1.49B	―	-15.59%	―	-35.41%	-12.26%
CDTX	57 Neutral	$1.43B	―	-299.58%	―	-99.35%	-260.33%
Sector *	54 Neutral	€4.73B	16.17	-48.29%	2.24%	15.31%	-8.26%
SRPT	47 Neutral	$1.31B	19.61	-23.61%	―	59.15%	-1881.09%
ELVN	36 Underperform	$1.32B	―	-31.30%	―	―	12.85%